Clinical trials of targeted neutrophil therapies for cancers aim to evaluate the safety, efficacy, and biological impact of novel interventions targeting key molecular pathways such as CXCR1/CXCR2, STAT3, IL-6, TGF-β, and Cluster of Differentiation 47—Signal Regulatory Protein Alpha (CD47-SIRPα). Here, SIRPA is linked to cancer.